Related Experiment Video
Updated: Jul 15, 2026
08:46
Real-time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels
Published on: March 22, 2024
C-type natriuretic peptide in individuals with normal left ventricular systolic function.
Jen-Yuan Kuo1, Hung-I Yeh, Sheng-Hsiung Chang
1Division of Cardiology, Department of Internal Medicine, Mackay Memorial Hospital, Mackay Medicine, Nursing, and Management College, and National Yang-Ming University, School of Medicine, Taipei, Taiwan.
Scandinavian Cardiovascular Journal : SCJ
|May 10, 2007
Summary
The heart muscle produces C-type natriuretic peptide (CNP) in individuals with normal heart function. Procedures like rapid pacing or electrophysiological studies do not alter CNP production or release.
Area of Science:
- Cardiology
- Biochemistry
- Physiology
Background:
- C-type natriuretic peptide (CNP) is primarily produced by the endothelium.
- Its role in myocardial function in individuals without heart failure is not well understood.
Purpose of the Study:
- To investigate the production or release of CNP in the myocardium of individuals without congestive heart failure (CHF).
Main Methods:
- Nineteen patients with paroxysmal supraventricular tachycardia (PSVT) and normal left ventricular (LV) systolic function were studied.
- Blood samples were collected from the coronary sinus (CS), femoral artery (FA), and peripheral vein (PV) at various time points: baseline, after rapid atrial pacing, and post-electrophysiological study (EPS) and/or radiofrequency (RF) ablation.
Main Results:
- CNP levels were significantly higher in the CS compared to FA and PV before pacing (p<0.001).
- Elevated CS CNP levels persisted after rapid atrial pacing (p=0.004) and post-EPS/RF ablation (p<0.01).
- These findings indicate consistent myocardial CNP production/release irrespective of pacing or ablation procedures.
Conclusions:
- The myocardium regularly produces or releases CNP in individuals with normal LV systolic function.
- Rapid atrial pacing, PSVT, and EPS/RF ablation do not significantly alter myocardial CNP production or release.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:17Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...